Irinotecan Fresenius Kabi (Irinotecan Hydrochloride Trihydrate)

After intravenous administration, Irinotecan is metabolised to SN‑38, an active compound that binds to the DNA‑topoisomerase I complex. This binding prevents the re‑ligation of single‑strand DNA breaks during replication, leading to accumulation of DNA damage, inhibition of tumour cell replication, and ultimately programmed cell death.

The dose of Irinotecan is individualized by the prescribing oncologist based on factors such as the specific cancer type, treatment protocol, patient weight, renal and hepatic function, and prior therapy. Only a qualified healthcare professional can determine the appropriate dosing schedule.

Safety data for Irinotecan in pregnancy and lactation are limited. It is generally classified as contraindicated during pregnancy unless the potential benefit justifies the risk to the fetus. Breastfeeding is not recommended while receiving Irinotecan because the drug may be excreted in milk and could harm the infant.

To place an order, submit an enquiry on the Irinotecan Fresenius Kabi product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Irinotecan is a pro‑drug that requires metabolic activation to SN‑38, whereas other topoisomerase I inhibitors such as topotecan are administered in active form. Irinotecan is commonly used in colorectal cancer regimens, while topotecan is often employed for ovarian and small‑cell lung cancers. Differences in pharmacokinetics, toxicity profiles and approved indications guide the choice between them.

Irinotecan injectable solution must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Prior to administration, the solution should be inspected for particulate matter and used within the time frame recommended by the manufacturer.

Irinotecan is given as an intravenous infusion, typically over 30 to 90 minutes depending on the treatment protocol. The infusion is performed by qualified healthcare personnel in a clinical setting, with appropriate monitoring for infusion‑related reactions and supportive measures for anticipated side effects.

The most critical risks include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhoea or colitis, and rare allergic reactions such as anaphylaxis. Prompt recognition and management of these events are essential; patients should be educated to report fever, persistent vomiting, or severe abdominal pain immediately.

Irinotecan is contraindicated in patients with known hypersensitivity to the drug or its excipients, in those with severe hepatic impairment, and in individuals who are pregnant unless the therapeutic benefit outweighs the risk. Caution is also advised for patients with pre‑existing bone‑marrow suppression or uncontrolled infections.